Objective:
The article examines the objective, findings, and clinical context described in Topcon Launches Oku Digital Health at AAO.
Approach:
- Source: Interview with Daniela Ferrara, MD, PhD, Topcon Healthcare chief medical officer, recorded at Eyecelerator during the 2026 AAO meeting.
- Concept: Oculomics uses biomarkers from retinal imaging and other ocular data to predict systemic diseases.
Key Findings:
- Topcon announced Oku Digital Health two days before the interview and planned to launch it at AAO the following day.
- Ferrara said she has diagnosed diabetes, high blood pressure, and neurological conditions during retinal examinations.
- The initiative aims to scale the use of ocular data for earlier, more precise diagnoses of systemic diseases.
- Topcon hopes to place devices in primary care offices, emergency rooms, and cardiology offices, as well as ophthalmology settings.
Interpretation:
Ferrara presented Oku Digital Health as an effort to advance oculomics research and extend ocular-data-based disease prediction beyond ophthalmology.
Limitations:
- The source is an interview transcript describing the initiative and its aims; it provides no study results or performance data.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







